Kidney Cancer Coverage from Every Angle
Advertisement
Advertisement

Recent News

Final Survival Analysis of Immotion151: Atezolizumab Plus Bevacizumab in Metastatic Kidney Cancer
Is Cabozantinib Effective After Progression of Metastatic Renal Cell Carcinoma?
Renal Cell Carcinoma and von Hippel–Lindau Disease: Focus on Belzutifan Treatment
Rare Case of Parotid Metastasis 8 Years After Nephrectomy
Risk of Kidney Cancer After Ranitidine Exposure: Danish Population–Based Study
Transcriptome Sequencing and T-Cell Receptor Spatial Mapping in Renal Cell Carcinoma
Is Coffee Intake Associated With a Decreased Risk of Renal Cell Cancer?
Stereotactic Body Radiation Therapy: Noninvasive Alternative to Treating Oligometastatic Kidney Cancer?
SITC 2021: Early-Phase Trial of Fc-Fusion Protein in Clear Cell Renal Cell Carcinoma
Ipilimumab Plus Nivolumab Therapy for Renal Cell Carcinoma With Brain Metastasis
SITC 2021: Interaction of Immune Checkpoint Inhibitors for Renal Cancer and COVID-19 Vaccination
Pembrolizumab Approved by FDA for Adjuvant Treatment of Renal Cell Carcinoma
Tumor Size Reduction and Survival Outcomes in Metastatic Renal Cell Carcinoma
Molecular Study Offers New Insights on Metastasis of Renal Cell Carcinoma
CONFIRM Study: Correlation Between Analgesic Use and Risk of Renal Cell Carcinoma?
Outcomes After Minimally Invasive Versus Open Radical Nephrectomy: Technique Matters
Can Prior Nephrectomy Improve Outcomes With Immunotherapy for Metastatic Kidney Cancer?
Can Proton Pump Inhibitors Improve Outcomes With Pazopanib in Renal Cell Carcinoma?
METEOR Trial of Cabozantinib Versus Everolimus in Advanced Kidney Cancer: Prognostic Plasma Biomarkers
CLEAR Trial in Advanced Kidney Cancer: Subgroup and Toxicity Update on Lenvatinib Plus Pembrolizumab
Cardiopulmonary Events: Study Finds Small but Real Risk After Partial Nephrectomy
ESMO 2021: Update From KEYNOTE-427 With Pembrolizumab Monotherapy for Kidney Cancer
Trends in Renal Cell Carcinoma in Pennsylvania Over the Past 27 Years
ESMO 2021: Patient-Reported Outcomes From KEYNOTE-564 With Adjuvant Pembrolizumab for Kidney Cancer
ESMO 2021: Can Modified Dosing Schedule of Ipilimumab Improve Tolerability in Renal Cell Carcinoma?
ESMO 2021: Temporary Treatment Cessation Versus Continuation in Advanced Kidney Cancer
ESMO 2021: 5-Year Outcomes With Nivolumab Plus Ipilimumab in Kidney Cancer
AUA 2021: Immunotherapy and Cytoreductive Nephrectomy in Metastatic Kidney Cancer
AUA 2021: Role of the Tumor Microenvironment and Response to Axitinib in Renal Cell Carcinoma
AUA 2021: KEYNOTE-564 Focuses on Adjuvant Immunotherapy for Renal Cell Carcinoma
Immune Checkpoint Inhibition in Metastatic Kidney Cancer: Racial Differences in Outcomes?
Reversible Aminotransferase Elevation in Patients Treated With Pembrolizumab/Axitinib for Kidney Cancer
Myasthenia Gravis: A Paraneoplastic Syndrome Linked to Renal Cell Carcinoma?
Renal Cell Carcinoma: Neoadjuvant Radiation Followed by Nephrectomy and Thrombectomy
Belzutifan Approved by FDA for von Hippel-Lindau Disease Associated With Kidney Cancer
Lenvatinib Plus Pembrolizumab Approved by FDA for Advanced Renal Cell Carcinoma
FDA Grants Priority Review to Pembrolizumab as Adjuvant Therapy After Nephrectomy
JAVELIN Renal 101 Trial: Second-Line Treatment With Axitinib Plus Avelumab in Kidney Cancer
MET-Driven Kidney Cancer: Combination of Durvalumab and Savolitinib Under Study
CheckMate 920: Nivolumab Plus Ipilimumab for Renal Cell Carcinoma With Brain Metastases
Can Nephrectomy Prior to Immunotherapy Improve Survival in Renal Cell Carcinoma?


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.